| Skeletal muscle wasting in chronic heart failure |
27 |
| Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes |
26 |
| Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience |
22 |
| Sex disparities in acute kidney injury complicating acute myocardial infarction with cardiogenic shock |
21 |
| Exercise and heart failure: an update |
20 |
| The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions |
18 |
| Performance of the MAGGIC heart failure risk score and its modification with the addition of discharge natriuretic peptides |
18 |
| Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis |
16 |
| Metabolic disorders in heart failure and cancer |
15 |
| Geriatric nutritional risk index predicts all-cause deaths in heart failure with preserved ejection fraction |
15 |
| Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction |
13 |
| Chloroquine-induced cardiomyopathy: a reversible cause of heart failure |
13 |
| A meta-analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients |
12 |
| Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction |
12 |
| Iron deficiency in chronic heart failure: case-based practical guidance |
12 |
| Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN |
12 |
| Design and rationale of haemodynamic guidance with CardioMEMS in patients with a left ventricular assist device: the HEMO-VAD pilot study |
12 |
| Machine learning-based prediction of heart failure readmission or death: implications of choosing the right model and the right metrics |
12 |
| Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan |
12 |
| Focused echocardiography and lung ultrasound protocol for guiding treatment in acute heart failure |
11 |
| Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis |
11 |
| Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study |
10 |
| Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan |
10 |
| Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis |
10 |
| Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines |
10 |
| Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH) |
10 |
| Peritoneal dialysis as therapeutic option in heart failure patients |
10 |
| Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK |
10 |
| Post-discharge short message service improves short-term clinical outcome and self-care behaviour in chronic heart failure |
10 |
| Highlights in heart failure |
10 |
| Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry (R) |
9 |
| Circulating markers of collagen types I, III, and IV in patients with dilated cardiomyopathy: relationships with myocardial collagen expression |
9 |
| Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease |
9 |
| Insights into implementation of sacubitril/valsartan into clinical practice |
9 |
| Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with pre-capillary pulmonary hypertension |
9 |
| Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy |
9 |
| Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as predictors of survival after heart transplantation |
9 |
| Full percutaneous biventricular support with two Impella pumps: the Bi-Pella approach |
8 |
| Autonomic dysfunction is associated with cardiac remodelling in heart failure patients |
8 |
| Transthyretin cardiac amyloidosis: an update on diagnosis and treatment |
8 |
| Human cardiomyocyte calcium handling and transverse tubules in mid-stage of post-myocardial-infarction heart failure |
8 |
| Assessing health-related quality of life in heart failure patients attending an outpatient clinic: a pragmatic approach |
8 |
| Early urine electrolyte patterns in patients with acute heart failure |
8 |
| Preliminary experience with the multisensor HeartLogic algorithm for heart failure monitoring: a retrospective case series report |
8 |
| Effects of elamipretide on skeletal muscle in dogs with experimentally induced heart failure |
8 |
| Strain-encoded magnetic resonance: a method for the assessment of myocardial deformation |
8 |
| The prognosis of mid-range ejection fraction heart failure: a systematic review and meta-analysis |
8 |
| Cost-effectiveness of a cardiac contractility modulation device in heart failure with normal QRS duration |
7 |
| Oral modified release morphine for breathlessness in chronic heart failure: a randomized placebo-controlled trial |
7 |
| Clinical profiles in acute heart failure: an urgent need for a new approach |
7 |
